| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS42000557 | EBV | ENSG00000108576.10 | protein_coding | SLC6A4 | No | No | 6532 | P31645 |
| TVIS20001603 | HPV | ENSG00000108576.10 | protein_coding | SLC6A4 | No | No | 6532 | P31645 |
| TVIS20029318 | HPV | ENSG00000108576.10 | protein_coding | SLC6A4 | No | No | 6532 | P31645 |
| TVIS20031248 | HPV | ENSG00000108576.10 | protein_coding | SLC6A4 | No | No | 6532 | P31645 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | SLC6A4 |
|---|---|
| DrugBank ID | DB01105 |
| Drug Name | Sibutramine |
| Target ID | BE0000749 |
| UniProt ID | P31645 |
| Regulation Type | inhibitor |
| PubMed IDs | 17544870; 17284621; 15685250; 16678551; 12417543; 15944869; 19475780; 18671470; 15382615; 10929704; 11152984 |
| Citations | Vazquez Roque MI, Camilleri M, Clark MM, Tepoel DA, Jensen MD, Graszer KM, Kalsy SA, Burton DD, Baxter KL, Zinsmeister AR: Alteration of gastric functions and candidate genes associated with weight reduction in response to sibutramine. Clin Gastroenterol Hepatol. 2007 Jul;5(7):829-37. Epub 2007 Jun 4.@@Heusser K, Engeli S, Tank J, Diedrich A, Wiesner S, Janke J, Luft FC, Jordan J: Sympathetic vasomotor tone determines blood pressure response to long-term sibutramine treatment. J Clin Endocrinol Metab. 2007 Apr;92(4):1560-3. Epub 2007 Feb 6.@@Jordan J, Scholze J, Matiba B, Wirth A, Hauner H, Sharma AM: Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials. Int J Obes (Lond). 2005 May;29(5):509-16.@@Heusser K, Tank J, Diedrich A, Engeli S, Klaua S, Kruger N, Strauss A, Stoffels G, Luft FC, Jordan J: Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects. Clin Pharmacol Ther. 2006 May;79(5):500-8.@@Birkenfeld AL, Schroeder C, Boschmann M, Tank J, Franke G, Luft FC, Biaggioni I, Sharma AM, Jordan J: Paradoxical effect of sibutramine on autonomic cardiovascular regulation. Circulation. 2002 Nov 5;106(19):2459-65.@@Birkenfeld AL, Schroeder C, Pischon T, Tank J, Luft FC, Sharma AM, Jordan J: Paradoxical effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patients--sibutramine and blood pressure. Clin Auton Res. 2005 Jun;15(3):200-6.@@Tziomalos K, Krassas GE, Tzotzas T: The use of sibutramine in the management of obesity and related disorders: an update. Vasc Health Risk Manag. 2009;5(1):441-52.@@Sharma B, Henderson DC: Sibutramine: current status as an anti-obesity drug and its future perspectives. Expert Opin Pharmacother. 2008 Aug;9(12):2161-73. doi: 10.1517/14656566.9.12.2161 .@@Gomis Barbara R: [Pharmacological treatment of obesity]. Rev Med Univ Navarra. 2004 Apr-Jun;48(2):63-5.@@Berke EM, Morden NE: Medical management of obesity. Am Fam Physician. 2000 Jul 15;62(2):419-26.@@Krahn LE, Moore WR, Altchuler SI: Narcolepsy and obesity: remission of severe cataplexy with sibutramine. Sleep Med. 2001 Jan;2(1):63-65. |
| Groups | Approved; Illicit; Investigational; Withdrawn |
| Direct Classification | Chlorobenzenes |
| SMILES | CC(C)CC(N(C)C)C1(CCC1)C1=CC=C(Cl)C=C1 |
| Pathways | |
| PharmGKB | PA451344 |
| ChEMBL | CHEMBL1419 |
